Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study

REFERENCES

1. 1.↵
   1. Salvarani C,
   2. Cantini F,
   3. Hunder GG

   . Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008;372:234–45.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Proven A,
   2. Gabriel SE,
   3. Orces C,
   4. O’Fallon WM,
   5. Hunder GG

   . Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003;49:703–8.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Martinez-Lado L,
   2. Calvino-Diaz C,
   3. Pineiro A,
   4. Dierssen T,
   5. Vazquez-Rodriguez TR,
   6. Miranda-Filloy JA,
   7. et al.

   Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine 2011;90:186–93.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Liozon E,
   2. Roblot P,
   3. Paire D,
   4. Loustaud V,
   5. Liozon F,
   6. Vidal E,
   7. et al.

   Anticardiolipin antibody levels predict flares and relapses in patients with giant-cell (temporal) arteritis. A longitudinal study of 58 biopsy-proven cases. Rheumatology 2000;39:1089–94.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Hachulla E,
   2. Boivin V,
   3. Pasturel-Michon U,
   4. Fauchais AL,
   5. Bouroz-Joly J,
   6. Perez-Cousin M,
   7. et al.

   Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis. Clin Exp Rheumatol 2001;19:171–6.

   OpenUrlPubMed
6. 6.↵
   1. Weyand CM,
   2. Fulbright JW,
   3. Hunder GG,
   4. Evans JM,
   5. Goronzy JJ

   . Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000;43:1041–8.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Garcia-Martinez A,
   2. Hernandez-Rodriguez J,
   3. Espigol-Frigole G,
   4. Prieto-Gonzalez S,
   5. Butjosa M,
   6. Segarra M,
   7. et al.

   Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis. Arthritis Care Res 2010;62:835–41.

   OpenUrlCrossRef
8. 8.↵
   1. Nesher G,
   2. Nesher R,
   3. Mates M,
   4. Sonnenblick M,
   5. Breuer GS

   . Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease. Clin Exp Rheumatol 2008;26:S30–4.

   OpenUrlPubMed
9. 9.↵
   1. Alba MA,
   2. Garcia-Martinez A,
   3. Prieto-Gonzalez S,
   4. Tavera-Bahillo I,
   5. Corbera-Bellalta M,
   6. Planas-Rigol E,
   7. et al.

   Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine 2014;93:194–201.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Ostberg G

    . Morphological changes in the large arteries in polymyalgia arteritica. Acta Med Scand (Suppl) 1972;533:135–59.

    OpenUrlPubMed
11. 11.↵
    1. Hoffman GS,
    2. Cid MC,
    3. Rendt-Zagar KE,
    4. Merkel PA,
    5. Weyand CM,
    6. Stone JH,
    7. et al.

    Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007;146:621–30.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Martinez-Taboada VM,
    2. Rodriguez-Valverde V,
    3. Carreno L,
    4. Lopez-Longo J,
    5. Figueroa M,
    6. Belzunegui J,
    7. et al.

    A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008;67:625–30.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Mahr AD,
    2. Jover JA,
    3. Spiera RF,
    4. Hernandez-Garcia C,
    5. Fernandez-Gutierrez B,
    6. Lavalley MP,
    7. et al.

    Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007;56:2789–97.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Aiello PD,
    2. Trautmann JC,
    3. McPhee TJ,
    4. Kunselman AR,
    5. Hunder GG

    . Visual prognosis in giant cell arteritis. Ophthalmology 1993;100:550–5.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Hoffman GS,
    2. Cid MC,
    3. Hellmann DB,
    4. Guillevin L,
    5. Stone JH,
    6. Schousboe J,
    7. et al.

    A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002;46:1309–18.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Chan CC,
    2. Paine M,
    3. O’Day J

    . Predictors of recurrent ischemic optic neuropathy in giant cell arteritis. J Neuroophthalmol 2005;25:14–7.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Jover JA,
    2. Hernandez-Garcia C,
    3. Morado IC,
    4. Vargas E,
    5. Banares A,
    6. Fernandez-Gutierrez B

    . Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;134:106–14.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Kyle V,
    2. Cawston TE,
    3. Hazleman BL

    . Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up. Ann Rheum Dis 1989;48:667–71.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Pountain GD,
    2. Calvin J,
    3. Hazleman BL

    . Alpha 1-antichymotrypsin, C-reactive protein and erythrocyte sedimentation rate in polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 1994;33:550–4.

    OpenUrlAbstract/FREE Full Text